Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.61 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069666 | 0.85 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL5205833 | 0.84 | PTGS2 (0.69) | PTGS2PTGS1IDO1 | |
| SCHEMBL6069872 | 0.83 | MAP4K4 (0.68) | PTGS2PTGS1IDO1MAP4K4PIK3CA | |
| SCHEMBL6069511 | 0.83 | PTGS2 (0.65) | PTGS2PTGS1IDO1PTGDR2MAP4K4 | |
| SCHEMBL6069630 | 0.81 | PTGS2 (0.66) | PTGS2PTGS1IDO1 | |
| SCHEMBL5208155 | 0.80 | PTGS2 (0.71) | PTGS2PTGS1IDO1 | |
| SCHEMBL5210900 | 0.80 | PTGS2 (0.78) | PTGS2PTGS1IDO1PTGDR2 | |
| SCHEMBL5205737 | 0.80 | PTGS2 (0.71) | PTGS2PTGS1IDO1 | |
| SCHEMBL6657716 | 0.78 | PTGS2 (0.80) | PTGS2PTGS1IDO1PTGDR2MAP4K4 | |
| SCHEMBL6169595 | 0.77 | PTGS2 (0.73) | PTGS2PTGS1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482456-B2 | antiasthmatic; antiinflammatory; minimal side effects; 8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline; 2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol | MERCK FROSST CANADA | 2009-01-27 | — | — | US | disclosed |
| CN-100441185-C | 8- (3-biaryl) phenylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA INC (CA) | 2008-12-10 | — | — | CN | disclosed |
| CN-1812787-A | 8- (3-biaryl) phenylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA INC (CA) | 2006-08-02 | — | — | CN | disclosed |
| US-7060715-B2 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-06-13 | — | — | US | disclosed |
| EP-1635829-A1 | 8-(3-BIARYL)PHENYLQUINOLINE PHOSPHODIESTERASE-4-INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | disclosed |
| EP-1015431-B1 | 2-AMINOPYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC (CA) | 2005-04-20 | — | — | EP | disclosed |
| US-20050009875-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK CANADA INC. (CA) | 2005-01-13 | — | — | US | disclosed |
| WO-2004096220-A1 | 8-(3-BIARYL)PHENYLQUINOLINE PHOSPHODIESTERASE-4-INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-11-11 | — | — | WO | disclosed |
| US-6812346-B2 | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS; ANALGESICS | MERCK FROSST CANADA AND CO. (CA) | 2004-11-02 | — | — | US | disclosed |
| EP-1012142-B1 | 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC (CA) | 2004-08-11 | — | — | EP | disclosed |
| EP-1012142-A1 | 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 | Merck Frosst Canada & Co. (CA) | 2000-06-28 | — | — | EP | disclosed |
| US-6071936-A | ANTIINFLAMMATORY AGENTS ANTIPYRETICS, ANALGESICS, ANTICARCINOGENIC AGENTS, SIDE EFFECT REDUCTION | MERCK FROSST CANADA & CO. (CA) | 2000-06-06 | — | — | US | disclosed |
| US-6046217-A | TREATING AN INFLAMMATORY DISEASE SUSCEPTIBLE TO TREATMENT WITH A NON-STEROIDAL ANTI-INFLAMMATORY AGENT COMPRISING ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A NONTOXIC 3-PHENYL SUBSTITUTED PYRIDINES | MERCK FROSST CANADA & CO. (CA) | 2000-04-04 | — | — | US | disclosed |
| US-6004950-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS; ANALGESIC, ANTIPYRETICS; SIDE EFFECT REDUCTION | MERCK FROSST CANADA, INC. (CA) | 1999-12-21 | — | — | US | disclosed |
| US-6001843-A | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK & CO., INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0912518-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-05-06 | — | — | EP | disclosed |
| WO-1999014195-A1 | 2-AMINOPYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA & CO. (CA) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999014194-A1 | 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA & CO. (CA) | 1999-03-25 | — | — | WO | disclosed |
| US-5861419-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; ETORICOXIB PATENT | MERCK FROSST CANAD, INC. (CA) | 1999-01-19 | — | — | US | disclosed |
| WO-1998003484-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009875-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885IDO1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.